CN115837016B - 一种aoa-2-pxb@lnp脂质纳米粒及制备方法 - Google Patents
一种aoa-2-pxb@lnp脂质纳米粒及制备方法 Download PDFInfo
- Publication number
- CN115837016B CN115837016B CN202310055291.3A CN202310055291A CN115837016B CN 115837016 B CN115837016 B CN 115837016B CN 202310055291 A CN202310055291 A CN 202310055291A CN 115837016 B CN115837016 B CN 115837016B
- Authority
- CN
- China
- Prior art keywords
- pxb
- aoa
- solution
- preparation
- ultrasonic treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 150000002632 lipids Chemical class 0.000 title claims abstract description 33
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 19
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 18
- 230000008685 targeting Effects 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000012528 membrane Substances 0.000 claims abstract description 9
- 230000001580 bacterial effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 36
- 238000009210 therapy by ultrasound Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 16
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 15
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000010025 steaming Methods 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 208000032376 Lung infection Diseases 0.000 claims description 6
- 108010093965 Polymyxin B Proteins 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229920000024 polymyxin B Polymers 0.000 claims description 5
- 229960005266 polymyxin b Drugs 0.000 claims description 5
- 229940126573 antibacterial therapeutic Drugs 0.000 claims description 3
- 230000036571 hydration Effects 0.000 claims description 3
- 238000006703 hydration reaction Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 18
- 208000015181 infectious disease Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 238000013461 design Methods 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 3
- 239000002502 liposome Substances 0.000 description 15
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 241000588626 Acinetobacter baumannii Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- -1 lipid compound Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KYHYBIADZPAZKE-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;bromide Chemical compound [Br-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KYHYBIADZPAZKE-LQDDAWAPSA-M 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- ZBZUNGODZBHLQD-WRBBJXAJSA-N C(CCCCCCC\C=C/CCCCCCCC)(=O)C(CCN(C)C)CC(CCCCCCC\C=C/CCCCCCCC)=O Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)C(CCN(C)C)CC(CCCCCCC\C=C/CCCCCCCC)=O ZBZUNGODZBHLQD-WRBBJXAJSA-N 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 101150042295 arfA gene Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 101150087557 omcB gene Proteins 0.000 description 1
- 101150115693 ompA gene Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- NRWCNEBHECBWRJ-UHFFFAOYSA-M trimethyl(propyl)azanium;chloride Chemical compound [Cl-].CCC[N+](C)(C)C NRWCNEBHECBWRJ-UHFFFAOYSA-M 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种AOA‑2‑PXB@LNP脂质纳米粒及制备方法,涉及医药技术领域,其技术要点为:包括以下步骤:S1、溶液配制;S2、制备PXB纳米粒;S3、制备脂质外膜。本发明的制备方法融合了精准靶向细菌本体或靶向感染部位的设计理念,将AOA‑2作为靶头的设计,利用了其靶向性而非简单的协同抗菌作用;此外,本发明的该制备方法使用PLGA搭载PXB,通过PLGA的缓释作用,增加感染部位的长效释放;通过该制备方法制得的制剂,能够增加PXB的局部浓度,减少大循环内的释放,增加抗菌效果的同时减少用量,起到增效减毒的作用。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种AOA-2-PXB@LNP脂质纳米粒及制备方法。
背景技术
多粘菌素是由广泛分布于土壤的多粘芽孢杆菌产生的一种具有抗菌活性的阳离子多肽,最早于1949年在日本发现,具有亲水和亲脂的双亲性。在临床上使用的仅有两种:多粘菌素B(po l ymyx i n B)和多粘菌素E(po l ymyx i n E)。多粘菌素B主要是以活性抗菌化合物硫酸多粘菌素B的形式作静脉给药,但是由于显著的肾毒性和神经毒性已经被弃用,近年来因为耐药问题的逐渐加重又重新启用,但是毒性问题仍未得到解决,并且也出现了多粘菌素耐药的菌株。
目前临床耐药问题严重,急需研发新抗生素,但是抗生素研发周期长,投入大,因此目前较好的解决方案是对现有抗生素进行改良。纳米抗生素就是一个重要的改良方向。纳米抗生素的研发方向目前有:1.本身具有抗菌效果的纳米材料,例如:纳米银、氧化铈等。2.利用纳米载体,改变抗生素的给药途径,例如:口服纳米抗生素中,纳米材料的主要作用是维持胃酸环境下药物的稳定性。3.具有控释效果,例如:可在炎症部位受到炎症因子的调控才释放,延长药物释放时间、增加药效等。
脂质体是由磷脂为膜材包合而成,磷脂是形成脂质体双分子层的基础物质,具有良好的生物相容性。在水中磷脂分子亲水头部插入水中,脂质体疏水尾部伸向空气,搅动后形成双层脂分子的球形脂质体。目前,除了mRNA疫苗递送,脂质体也被广泛运用在各大疾病治疗领域。我们使用的DOTAP是阳离子脂质体研究中常用的脂质,化学名为(溴化三甲基-2,3-二油酰氧基丙基铵,分子式C42H80NO4C l,分子量698.6),是一种带正电荷的两亲性类脂化合物。由于其带正电荷的特性易于被肺等疏松组织吸附,具有一定的器官特异性。目前常用于核酸和蛋白质递送,较少应用于小分子化合物。
聚乳酸-羟基乙酸共聚物(po l y(l act i c-co-g l yco l i c ac i d),PLGA)由两种单体——乳酸和羟基乙酸随机聚合而成,是一种可降解的功能高分子有机化合物,具有良好的生物相容性、无毒、良好的成囊和成膜的性能,被广泛应用于制药、医用工程材料和现代化工业领域。在美国PLGA通过FDA认证,被正式作为药用辅料收录进美国药典。
为起到特异性靶向细菌外膜的效果,本申请发明人选取了OmpA这一蛋白作为靶点。OmpA在细菌外膜上广泛表达,在革兰氏阴性菌外膜表面尤其多,且在进化上非常保守。有研究团队根据它的空间结构设计了可与其相互作用的小分子多肽AOA-2,假设OmpA的大小和形状可能允许容纳六肽配体,考虑到环化可能增加蛋白水解的抗性并抑制肽序列的构象灵活性,于是设计了一个对称环状六肽的虚拟库作为潜在的OmpA结合剂。所有环状六肽都含有两个固定的脯氨酸残基以促进环化。随后根据大肠杆菌和鲍曼不动杆菌的OmpA的TM结构域对该肽库进行了计算筛选,并根据评分函数进行排序,验证了其分别在体外与体内与抗生素间的协同抗菌作用(Parra-M i l lán et al.,2018,Ayerbe-Al gaba et al.,2021)。说明了AOA-2具有增强抗生素对革兰氏阴性菌抗菌效果的作用。但是并没有利用具有与OmpA空间结构相互作用的特性,将其作为靶头应用于纳米抗生素的递送,以增加抗生素的靶向性。
现有的PXB纳米剂型改良方案:
1.改变PXB的使用途径:
1)口服:治疗囊性纤维化、肺炎、菌血症、尿路感染
2)吸入:治疗囊性纤维化、肺炎
3)局部使用:眼科治疗
2.直接对多粘菌素B结构进行改良的方案:
1)PXB主氨基和肉桂醛羰基间建立亚胺键,增加药物亲脂性和分子极性,减慢药物释放。
2)PXB与聚乙二醇甲基醚丙烯酸酯(PEGA-480)生物结合物,体外抑菌活性更好。
3)PXB与金纳米粒子使用聚乙二醇作为连接剂结合。
因此,现有技术中的PXB纳米制剂存在以下缺陷:
1、目前的PXB纳米制剂,主要是为了改变给药途径和增加抗菌效果,并没有针对感染局部及细菌本身精准抗菌的设计。
2、研发成本高,不易实现快速转化。
为此,本发明旨在提供一种AOA-2-PXB@LNP脂质纳米粒及制备方法,以解决上述问题。
发明内容
本发明的目的是为了解决上述问题,提供一种AOA-2-PXB@LNP脂质纳米粒及制备方法。
为了达到上述目的,本发明的技术方案如下:一种AOA-2-PXB@LNP脂质纳米粒的制备方法,包括以下步骤:
S1、溶液配制:
将AOA-2溶于水配置成50mg/ml溶液;将PXB溶于水配置成100mg/m l溶液;将PVA溶于水配置成0.01mg/ml的水溶液;将PLGA溶于二氯甲烷配置成20mg/m l溶液;将DOTAP溶于无水乙醇配置成10mg/ml溶液;将DSPC溶于无水乙醇配置成20mg/ml溶液;将Cho l溶于无水乙醇配置成10mg/m l溶液,备用;
S2、制备PXB纳米粒:
取20mg PLGA、200u l丙酮及5mg PXB,于100w冰浴超声6mi n,超声5s暂停5s;取4ml 0.22um注射器过滤器过滤后的1%PVA水溶液,加入超声后的混合物中;继续于100w冰浴超声6mi n,超声5s停5s;超声后,37℃减压旋蒸5mi n至气泡消失,溶液呈珠光色均匀分散,即得PXB纳米粒溶液;
S3、制备脂质外膜:
根据比例分别取DOTAP、DSPC、Cho l、AOA-2溶液进行超声混匀后,37℃减压旋蒸20mi n成脂质薄膜;将步骤S2中制得的PXB纳米粒溶液加入成好的脂质薄膜中,40℃旋蒸水化10mi n;最终将得到的脂质纳米粒再次80w冰浴超声6mi n,超声3s,停3s,获得制备好的AOA-2-PXB@LNP脂质纳米粒。
进一步地,所述DOTAP、DSPC和Cho l为PXB纳米脂质体的组成组分,且所述DOTAP、DSPC和Cho l的配比为1:4:3。
本发明还提供了基于上述一种AOA-2-PXB@LNP脂质纳米粒的制备方法制得的脂质纳米粒的应用,即将所述AOA-2-PXB@LNP脂质纳米粒用于精准靶向肺部感染及细菌本体的抗菌治疗药物的制备。
本发明的方案中,提出了精准靶向肺部感染及细菌本体的抗菌治疗的概念;该制备方法利用了AOA-2和OmpA结构上的相互作用,将AOA-2作为靶头使用而非共同给药,利用了其空间结构的靶向性而非简单的协同抗菌作用;该制备方法使用PLGA搭载PXB,通过PLGA的缓释作用,增加感染部位的长效释放。通过该制备方法制得的制剂,能够增加PXB在感染局部的浓度,减少非靶向部位的药物浓度,增强抗菌效果的同时减少用量,起到增效减毒的作用。
与现有技术相比,本方案的有益效果:
1、本发明的制备方法融合了精准靶向细菌本体或靶向感染部位的设计理念,将AOA-2作为靶头的设计,利用了其靶向性而非简单的协同抗菌作用;
2、本发明的该制备方法使用PLGA搭载PXB,通过PLGA的缓释作用,增加感染部位的长效释放;通过该制备方法制得的制剂,能够增加PXB在感染局部的浓度,减少非靶向部位的药物浓度,增强抗菌效果的同时减少用量,起到增效减毒的作用;
3、本发明的制备方法简单,材料容易获得;
4、该制备方法提供了一种递送模型,对进一步改良其他抗生素具有指导意义,有助于重新启用因耐药问题或毒性问题逐渐淡出临床应用的抗生素。
附图说明
图1是本发明实施例中搭载D I D荧光染剂的AOA-2@LNP给药2小时后在鲍曼不动杆菌肺炎模型小鼠体内的分布;
图2是本发明实施例中分别给予鲍曼不动杆菌肺炎模型小鼠AOA-2@LNP、PXB游离药物、无AOA-2靶头的PXB@LNP制剂及AOA-2-PXB@LNP制剂后小鼠的生存曲线;
图3是本发明实施例中无AOA-2靶头的PXB@LNP制剂、PXB游离药物及AOA-2-PXB@LNP制剂的最低抑菌浓度(M I C)值;
图4是本发明实施例中透射电镜下AOA-2@LNP及AOA-2-PXB@LNP的形态;
图5是本发明实施例中用药后不同组别肺泡灌洗液性状;
图6是本发明实施例中PXB及AOA-2-PXB@LNP体外抗菌荧光染色;
图7是本发明实施例中体内外安全性。
具体实施方式
为了使本技术领域的人员更好地理解本发明方案,下面将结合本发明的实施例及附图,对本发明的技术方案进行进一步详细地描述,显然,所描述的实施例仅仅是本发明一部分的实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。
需要说明的是,在不冲突的情况下,本发明中的实施例及实施例中的特征可以相互组合。下面将结合实施例来详细说明本发明。
术语解释:
DOTAP:(2,3-二油酰基-丙基)-三甲胺;PXB:po l ymyx i n B,多粘菌素B;PLGA:po l y(l act i c-co-g l yco l i c ac i d,聚乳酸-羟基乙酸共聚物;OmpA:Outermembrane prote i n A,外膜蛋白A;DSPC:1,2-D i octadecanoy l-sn-g l ycero-3-phophocho l i ne,二硬脂酰磷脂酰胆碱;Cho l:胆固醇;PVA:Po l y(v i ny l a l cohol),聚乙烯醇。
实施例:
本发明实施例提供的方案为:一种AOA-2-PXB@LNP脂质纳米粒的制备方法,包括以下步骤:
S1、溶液配制:
将AOA-2(购入AOA-2靶头,结构为:&Trp-D-Pro-Arg-Trp-D-Pro-Arg&。设计及制备方法见(Vi l a-Farrés et a l.,2017)、PLGA、DOTAP等)溶于水配置成50mg/m l溶液;将PXB溶于水配置成100mg/ml溶液;将PVA溶于水配置成0.01mg/ml的水溶液;将PLGA溶于二氯甲烷配置成20mg/m l溶液;将DOTAP溶于无水乙醇配置成10mg/ml溶液;将DSPC溶于无水乙醇配置成20mg/m l溶液;将Cho l溶于无水乙醇配置成10mg/ml溶液,备用;
S2、制备PXB纳米粒:
取20mg PLGA、200u l丙酮及5mg PXB,于100w冰浴超声6mi n,且超声5s暂停5s;使用0.22um注射器过滤器过滤配置好的PVA水溶液后,并取4m l PVA水溶液加入超声后的混合物中;继续于100w下冰浴超声6mi n,且超声5s停5s;超声后,37℃减压旋蒸5mi n,至气泡消失溶液呈珠光色均匀分散,即得PXB纳米粒溶液;
S3、制备脂质外膜:
取2mg(200u l)DOTAP、8mg(350u l)DSPC、6mg(300u l)Cho l、5mg(100u l)AOA-2超声混匀后,37℃减压旋蒸20mi n成脂质薄膜;将步骤S2中制得的PXB纳米粒溶液加入成好的脂质薄膜中,40℃旋蒸水化10mi n;最终将得到的脂质纳米粒再次80w冰浴超声6mi n,超声3s,停3s,获得制备好的AOA-2-PXB@LNP脂质纳米粒。
本发明将采用上述方法制得的AOA-2-PXB@LNP脂质纳米粒用于精准靶向肺部感染及细菌本体的抗菌治疗药物的制备。
在本发明中,上述制备方法中,载体为阳离子脂质体,即DOTAP;因此除了DOTAP,DOTMA(二油酰丙基氯化三甲铵)、D I MRI E和DOT I M都可以作为载体,作为替代方案。此外,除了可特异性聚集在肺部,阳离子脂质体还易于靶向肝脏,因此除了靶向肺部感染外,靶向肝脏感染也可以作为替代方案。
以下为找出本发明制备的制剂的最佳配方并验证药效的相关实验:
1、筛选配方
1)为了筛选出最佳配方,对脂质体及纳米脂质体配比进行筛选如下表1所示,结果提示纳米脂质体包封率及载药量较脂质体更高。
表1.脂质体和纳米脂质体的筛选配方
2)对纳米脂质体的配比进行筛选
如下表2所示,最终根据ZETA电位及包封率,选择1:4:3作为纳米脂质体配方。
表2
2.分布及药效试验
1)分布实验
如图1所示,为搭载D I D荧光染剂的AOA-2@LNP给药2小时后在鲍曼不动杆菌肺炎模型小鼠体内的分布。
2)体内药效
如图2所示,其为分别给予鲍曼不动杆菌肺炎模型小鼠AOA-2@LNP、PXB游离药物、无AOA-2靶头的PXB@LNP制剂及AOA-2-PXB@LNP制剂后小鼠的生存曲线。如图5所示,AOA-2-PXB@LNP较其他各组肺泡内出血显著减少,提示AOA-2-PXB@LNP有明确的肺保护作用。
3)体外药效
如图3所示,其为无AOA-2靶头的PXB@LNP制剂、PXB游离药物及AOA-2-PXB@LNP制剂的最低抑菌浓度(M I C)值。如图6所示,PI染色提示死亡细菌,可见AOA-2-PXB@LNP较PXB游离药抗菌效果有显著提升。
4)安全性
如图7所示,体内外安全性实验均提示AOA-2-PXB@LNP较PXB游离药安全性无显著差异。
综上所述,结果提示筛选后的PXB纳米脂质体AOA-2-PXB@LNP具有良好的靶向肺部感染部位的效果,并同时抗菌效果也明显增强。
通过本发明的上述实施例,本发明的制备方法融合了精准靶向细菌本体或靶向感染部位的设计理念,将AOA-2作为靶头的设计,利用了其靶向性而非简单的协同抗菌作用;此外,本发明的该制备方法使用PLGA搭载PXB,通过PLGA的缓释作用,增加感染部位的长效释放;通过该制备方法制得的制剂,能够增加PXB的局部浓度,减少大循环内的释放,增效的同时减少用量,起到减毒的作用。
以上具体实施例仅仅是对本发明的解释,其并不是对本发明的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本发明的权利要求范围内都受到专利法的保护。
Claims (2)
1.一种AOA-2-PXB@LNP脂质纳米粒的制备方法,其特征是:包括以下步骤:
S1、溶液配制:
将AOA-2溶于水配置成50mg/ml溶液;将PXB溶于水配置成100mg/ml溶液;将PVA溶于水配置成0.01mg/ml的水溶液;将PLGA溶于二氯甲烷配置成20mg/ml溶液;将DOTAP溶于无水乙醇配置成10mg/ml溶液;将DSPC溶于无水乙醇配置成20mg/ml溶液;将Chol溶于无水乙醇配置成10mg/ml溶液,备用;
S2、制备PXB纳米粒:
取20mg PLGA、200ul丙酮及5mg PXB,于100w冰浴超声6min,超声5s暂停5s;取4ml0.22um注射器过滤器过滤后的1% PVA水溶液,加入超声后的混合物中;继续于100w冰浴超声6min,超声5s停5s;超声后,37℃减压旋蒸5min至气泡消失,溶液呈珠光色均匀分散,即得PXB纳米粒溶液;
S3、制备脂质外膜:
根据比例分别取DOTAP、DSPC、Chol、AOA-2溶液进行超声混匀后,37℃减压旋蒸20min成脂质薄膜;将步骤S2中制得的PXB纳米粒溶液加入成好的脂质薄膜中,40℃旋蒸水化10min;最终将得到的脂质纳米粒再次80w冰浴超声6min,超声3s,停3s,获得制备好的AOA-2-PXB@LNP脂质纳米粒;
所述DOTAP、DSPC和Chol为PXB纳米脂质体的组成组分,且所述DOTAP、DSPC、Chol和AOA-2溶液的质量配比为1:4:3:2.5;所述PXB为多粘菌素B;所述AOA-2的结构为:&Trp-D-Pro-Arg-Trp-D-Pro-Arg&。
2.如权利要求1所述的一种AOA-2-PXB@LNP脂质纳米粒的制备方法,其特征是:所述AOA-2-PXB@LNP脂质纳米粒用于精准靶向肺部感染及细菌本体的抗菌治疗药物的制备。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310055291.3A CN115837016B (zh) | 2023-02-04 | 2023-02-04 | 一种aoa-2-pxb@lnp脂质纳米粒及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310055291.3A CN115837016B (zh) | 2023-02-04 | 2023-02-04 | 一种aoa-2-pxb@lnp脂质纳米粒及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115837016A CN115837016A (zh) | 2023-03-24 |
CN115837016B true CN115837016B (zh) | 2024-02-27 |
Family
ID=85579549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310055291.3A Active CN115837016B (zh) | 2023-02-04 | 2023-02-04 | 一种aoa-2-pxb@lnp脂质纳米粒及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115837016B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016046397A1 (en) * | 2014-09-25 | 2016-03-31 | Servicio Andaluz De Salud | Cyclic peptides against the outer membrane protein a (ompa) for the treatment of infections caused by gram negative pathogens |
-
2023
- 2023-02-04 CN CN202310055291.3A patent/CN115837016B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016046397A1 (en) * | 2014-09-25 | 2016-03-31 | Servicio Andaluz De Salud | Cyclic peptides against the outer membrane protein a (ompa) for the treatment of infections caused by gram negative pathogens |
Non-Patent Citations (1)
Title |
---|
AOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections;Rafael Ayerbe-Algaba;《Frontiers in Microbiology》;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN115837016A (zh) | 2023-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Infection microenvironment-related antibacterial nanotherapeutic strategies | |
US7901707B2 (en) | Biodegradable biocompatible implant and method of manufacturing same | |
Yang et al. | Chitosan coated vancomycin hydrochloride liposomes: characterizations and evaluation | |
Wu et al. | Genipin-crosslinked carboxymethyl chitosan nanogel for lung-targeted delivery of isoniazid and rifampin | |
CN101785861B (zh) | 用于药理活性化合物的可控释放的可注射组合物 | |
CN102292069B (zh) | 囊泡制剂 | |
US20050260260A1 (en) | Liposome compositions for the delivery of macromolecules | |
AU2008359989A1 (en) | Drug carriers | |
JP5429642B2 (ja) | 薬剤の局所導出を対象とした注射可能なポリマー/脂質ブレンド | |
TWI732773B (zh) | 用於奈米顆粒冷凍乾燥形式的組成物及方法 | |
AU2016226151B2 (en) | Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent | |
CN109771663B (zh) | 一种酸响应性抗癌纳米药物的制备及应用 | |
Ma et al. | Knee osteoarthritis therapy: recent advances in intra-articular drug delivery systems | |
Maxwell et al. | Breaking the barriers for the delivery of amikacin: Challenges, strategies, and opportunities | |
WO2008080369A1 (fr) | Composition liposomale stable | |
CN109771660A (zh) | 一种具有pH响应果胶-阿霉素/雷公藤红素纳米粒子的制备 | |
CN115837016B (zh) | 一种aoa-2-pxb@lnp脂质纳米粒及制备方法 | |
Peng et al. | Gout therapeutics and drug delivery | |
CN114040782A (zh) | 跨鼓膜递送平台及其用途 | |
JP2019500406A (ja) | 抗癌薬の新規ナノ製剤及びその製造方法 | |
Wu et al. | Molecular engineering of polymyxin B for imaging and treatment of bacterial infections | |
KR101477928B1 (ko) | 암 치료를 위한 pH 민감성 나노운반체 및 그의 제조방법 | |
AU2020295730A1 (en) | Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament | |
Liu et al. | Prolonged systemic delivery of antibacterial agent levofloxacin using liposomes. | |
JP2020521004A (ja) | c(RGD−ACP−K)修飾血中滞留型リポソーム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |